Opinion: What defines high-risk CLL in the post-chemoimmunotherapy era?
| Authors | |
|---|---|
| Year of publication | 2023 |
| Type | Article in Periodical |
| Magazine / Source | Frontiers in Oncology |
| MU Faculty or unit | |
| Citation | |
| Web | https://www.frontiersin.org/articles/10.3389/fonc.2023.1106579/full |
| Doi | http://dx.doi.org/10.3389/fonc.2023.1106579 |
| Keywords | chronic lymphocytic leukemia (CLL); high-risk; TP53; definition; BTK - Bruton's tyrosine kinase; BCL2 (B-cell lymphoma 2); COVID-19; risk factor |
| Attached files | |
| Description | The definition of high-risk chronic lymphocytic leukemia (CLL) was relatively simple in the chemoimmunotherapy era, as it was defined by only one genomic marker, TP53 alteration, along with poor responses to purine-analogue based treatment. While other biomarkers such as unmutated IGHV, del(11q), high ZAP70 expression and high CD38 expression were associated with inferior prognosis, TP53 deficiency by mutation and/or del(17p) remained the only biomarker that clearly guided treatment decisions. |
| Related projects: |